News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,941 Results
Type
Article (13488)
Company Profile (103)
Press Release (245350)
Section
Business (87827)
Career Advice (460)
Deals (15317)
Drug Delivery (60)
Drug Development (36467)
Employer Resources (49)
FDA (6234)
Job Trends (6178)
News (149745)
Policy (13992)
Tag
Academia (435)
Africa (312)
Alliances (23036)
Alzheimer's disease (322)
Approvals (6215)
Arizona (35)
Artificial intelligence (40)
Asia (19637)
Australia (2532)
Bankruptcy (143)
Best Places to Work (4199)
Biosimilars (31)
Biotechnology (43)
C2C Services and Suppliers (10596)
California (597)
Canada (435)
Cancer (146)
Career advice (402)
Cell therapy (23)
China (66)
Clinical research (30052)
Collaboration (53)
Compensation (26)
Connecticut (24)
COVID-19 (737)
Cystic fibrosis (21)
Data (101)
Diabetes (26)
Diagnostics (1201)
Drug pricing (47)
Earnings (31140)
Employer resources (43)
Europe (38398)
Events (36264)
Executive appointments (83)
FDA (6301)
Florida (74)
Funding (38)
Gene therapy (40)
GLP-1 (259)
Government (1249)
Healthcare (3504)
Hotbed/Location (177909)
Illinois (70)
Indiana (59)
Infectious disease (741)
Inflammatory bowel disease (41)
Interviews (57)
IPO (5782)
IRA (22)
Job creations (2046)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (33)
Manufacturing (45)
Maryland (89)
Massachusetts (526)
Medical device (1251)
Medtech (1253)
Mergers & acquisitions (9475)
Metabolic disorders (100)
Minnesota (37)
Neuroscience (375)
New Jersey (247)
New York (165)
NextGen Class of 2024 (1576)
Non-profit (588)
North Carolina (223)
Northern California (265)
Obesity (60)
Ohio (29)
Opinion (106)
Patents (40)
Pennsylvania (185)
People (28234)
Pharmaceutical (59)
Phase I (7820)
Phase II (12703)
Phase III (11415)
Pipeline (49)
Podcasts (35)
Policy (36)
Postmarket research (1398)
Preclinical (3128)
Press Release (25)
Rare diseases (51)
Real estate (2624)
Regulatory (9691)
Research institute (561)
Resumes & cover letters (55)
South America (497)
Southern California (266)
Startups (1623)
Texas (80)
United States (2640)
Vaccines (91)
Washington State (46)
Weight loss (52)
Date
Today (23)
Last 7 days (218)
Last 30 days (769)
Last 365 days (13315)
2024 (9297)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13891)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,941 Results for "kalvista pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on June 3, 2024 as inducement material to such employee entering into employment with KalVista.
June 4, 2024
·
1 min read
Genetown
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - May 21, 2024
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced its management will participate in fireside chats at the following upcoming conferences.
May 21, 2024
·
3 min read
Genetown
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2024
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of KalVista common stock on May 1, 2024 as inducements material to each employee entering into employment with KalVista.
May 2, 2024
·
1 min read
Business
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
KalVista Pharmaceuticals, Inc. announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately.
April 22, 2024
·
4 min read
Drug Development
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024.
June 6, 2024
·
7 min read
Genetown
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year 2025
KalVista Pharmaceuticals, Inc., announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
May 1, 2024
·
5 min read
Genetown
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista.
April 2, 2024
·
1 min read
Genetown
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KalVista Pharmaceuticals, Inc., announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema.
June 27, 2024
·
3 min read
Genetown
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
KalVista Pharmaceuticals, Inc., announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain.
June 3, 2024
·
7 min read
Genetown
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals, Inc. announced its management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 10:15 a.m. ET.
April 3, 2024
·
2 min read
1 of 25,895
Next
